Tc-99m tilmanocept

Phase 2Protein / enzyme

NNavidea Biopharmaceuticals

Tc-99m tilmanocept is one of 59 small molecule programs targeting Metastatic Melanoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic MelanomaActive, not recruiting

Cardiac SarcoidosisActive, not recruiting

Metastatic MelanomaPhase 1

Active, not recruiting

Cardiac SarcoidosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Metastatic Melanoma

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

23 2

DTIC-Dome

Bayer

Phase 3

17 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

46 4

Taxol

Teva

Phase 3

7 5

Mektovi

Pfizer

Phase 3

7 6

Cotellic

Roche

Phase 3

6 7

Braftovi

Pfizer

Phase 3

6 8

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

17 9

Fabhalta

Regeneron

Phase 3

1 10

Libtayo

Regeneron

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Cardiac Sarcoidosis

NCT07159074

Clinical

Trials by Indication[1]

Imaging2 trials

Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA

Terminated·NNavidea Biopharmaceuticals·Phase 2·NCT04078191·20 enrolled

Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging

Completed·NNavidea Biopharmaceuticals·Phase 2·NCT03938636·116 enrolled

Metastatic Melanoma1 trial

Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma

Terminated·JJohn O. Prior·Phase 1·NCT04663126·5 enrolled

Cardiac Sarcoidosis1 trial

Repurposing Tilmanocept for Cardiac Sarcoidosis

Recruiting·—·Phase 2·NCT07159074·15 enrolled

CNS Malignancies1 trial

Mapping Draining Lymph Nodes in CNS Malignancies

Terminated·WWashington University School of Medicine·Phase 1·NCT04096716·14 enrolled

Kaposi's sarcoma1 trial

Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT

Completed·NNavidea Biopharmaceuticals·Phase 2·NCT02201420·5 enrolled

1 more indication

Unspecified1 trial

Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy

Unknown status·MMemorial Health University Medical Center·Phase 4·NCT03199560·86 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Tc-99m tilmanocept. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tc-99m tilmanocept compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tc-99m tilmanocept. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Navidea Biopharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: NNavidea Biopharmaceuticals

Tc-99m tilmanocept

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Imaging2 trials

Metastatic Melanoma1 trial

Cardiac Sarcoidosis1 trial

CNS Malignancies1 trial

Kaposi's sarcoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News